Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Individual prediction model for lamivudine treatment response in hepatitis B virus e antigen-positive chronic hepatitis B patients.

Lee HW, Kang W, Ahn SH, Lee HJ, Hwang JS, Sohn JH, Jang JY, Han KJ, Kim JK, Kim DY, Paik YH, Lee CK, Choi IS, Lee KS, Han KH.

J Gastroenterol Hepatol. 2014 May;29(5):1049-55. doi: 10.1111/jgh.12522.

PMID:
24575848
2.

Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.

Pellicelli AM, Barbaro G, Francavilla R, Romano M, Barbarini G, Mazzoni E, Mecenate F, Paffetti A, Barlattani A, Struglia C, Villani R, Nauri L, Nosotti L, Armignacco O, Ferri F, Camporiondo MP, Soccorsi F; Club Epatologi Ospedalieri (CLEO) Group..

Clin Ther. 2008 Feb;30(2):317-23. doi: 10.1016/j.clinthera.2008.02.012.

PMID:
18343270
3.

Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion.

Kuo YH, Chen CH, Wang JH, Hung CH, Tseng PL, Lu SN, Changchien CS, Lee CM.

Scand J Gastroenterol. 2010;45(1):75-81. doi: 10.3109/00365520903394550.

PMID:
20030580
4.

Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.

Vassiliadis TG, Giouleme O, Koumerkeridis G, Koumaras H, Tziomalos K, Patsiaoura K, Grammatikos N, Mpoumponaris A, Gkisakis D, Theodoropoulos K, Panderi A, Katsinelos P, Eugenidis N.

J Gastroenterol Hepatol. 2010 Jan;25(1):54-60. doi: 10.1111/j.1440-1746.2009.05952.x. Epub 2009 Sep 22.

PMID:
19780875
5.

Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir.

Ze E, Baek EK, Lee JJ, Chung HW, Ahn DG, Cho HJ, Kwon JC, Kim HJ, Lee H.

Clin Mol Hepatol. 2014 Sep;20(3):267-73. doi: 10.3350/cmh.2014.20.3.267. Epub 2014 Sep 25.

6.

Clinical significance of hepatitis B e antigen level measurement during long-term lamivudine therapy in chronic hepatitis B patients with e antigen positive.

Shin JW, Park NH, Jung SW, Kim BC, Kwon SH, Park JS, Jeong ID, Bang SJ, Kim DH.

World J Gastroenterol. 2006 Nov 7;12(41):6693-8.

7.

Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.

Maklad S, Doss W, El Din SS, Hassan K, Zeid AA.

Arab J Gastroenterol. 2014 Mar;15(1):1-5. doi: 10.1016/j.ajg.2014.01.003. Epub 2014 Feb 4.

PMID:
24630505
8.

A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients.

Tseng TC, Liu CJ, Wang CC, Chen PJ, Lai MY, Kao JH, Chen DS.

Liver Int. 2008 Aug;28(7):1034-41. doi: 10.1111/j.1478-3231.2008.01766.x. Epub 2008 May 19.

PMID:
18492018
9.

Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion.

Yoon SK, Jang JW, Kim CW, Bae SH, Choi JY, Choi SW, Lee YS, Lee CD, Chung KW, Sun HS, Kim BS.

Intervirology. 2005;48(6):341-9.

PMID:
16024938
10.

Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase.

van Nunen AB, Hansen BE, Suh DJ, Löhr HF, Chemello L, Fontaine H, Heathcote J, Song BC, Janssen HL, de Man RA, Schalm SW.

Gut. 2003 Mar;52(3):420-4.

11.

Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B.

Lee HW, Lee HJ, Hwang JS, Sohn JH, Jang JY, Han KJ, Park JY, Kim DY, Ahn SH, Paik YH, Lee CK, Lee KS, Chon CY, Han KH.

Hepatology. 2010 Feb;51(2):415-21. doi: 10.1002/hep.23323.

PMID:
19902424
12.

Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients.

Buti M, Elefsiniotis I, Jardi R, Vargas V, Rodriguez-Frias F, Schapper M, Bonovas S, Esteban R.

J Hepatol. 2007 Sep;47(3):366-72. Epub 2007 May 24.

PMID:
17561304
13.

Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients.

Idilman R, Cinar K, Seven G, Bozkus Y, Elhan A, Bozdayi M, Yurdaydin C, Bahar K.

J Viral Hepat. 2012 Mar;19(3):220-6. doi: 10.1111/j.1365-2893.2011.01542.x. Epub 2011 Oct 19.

PMID:
22329377
14.

Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.

Sarin SK, Kumar M, Kumar R, Kazim SN, Guptan RC, Sakhuja P, Sharma BC.

Am J Gastroenterol. 2005 Nov;100(11):2463-71.

PMID:
16279901
15.

The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion.

Fung J, Lai CL, Tanaka Y, Mizokami M, Yuen J, Wong DK, Yuen MF.

Am J Gastroenterol. 2009 Aug;104(8):1940-6; quiz 1947. doi: 10.1038/ajg.2009.200. Epub 2009 May 19.

PMID:
19455108
16.

[Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].

Zhou HJ, Li SG, Wen FY, Yang XY, Wu JL, Tan B, Fu J.

Zhonghua Gan Zang Bing Za Zhi. 2009 Aug;17(8):564-8. Chinese.

PMID:
19719911
17.

Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.

Wong VW, Wong GL, Tsang SW, Hui AY, Chim AM, Yiu KK, Chan HY, Chan FK, Sung JJ, Chan HL.

Antivir Ther. 2008;13(4):571-9.

PMID:
18672536
18.

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea.

Song BC, Suh DJ, Lee HC, Chung YH, Lee YS.

Hepatology. 2000 Oct;32(4 Pt 1):803-6.

PMID:
11003626
19.

A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients.

Idilman R, Kaymakoglu S, Oguz Onder F, Ahishali E, Bektas M, Cinar K, Pinarbasi B, Karayalcin S, Badur S, Cakaloglu Y, Mithat Bozdayi A, Bozkaya H, Okten A, Yurdaydin C.

J Viral Hepat. 2009 Apr;16(4):279-85. doi: 10.1111/j.1365-2893.2009.01074.x. Epub 2009 Feb 12.

PMID:
19222742
20.

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.

Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RN; Asia Hepatitis Lamivudine Study Group..

Hepatology. 2001 Jun;33(6):1527-32.

PMID:
11391543

Supplemental Content

Support Center